FibroTest is a noninvasive blood test that estimates liver fibrosis, which means scarring inside the liver. In the United States, the same test is commonly reported under the name FibroSure. Instead of removing a small piece of liver tissue with a biopsy, FibroTest combines several blood markers with age and sex to produce a score from 0.00 to 1.00. Lower scores usually suggest little or no fibrosis, while higher scores suggest more advanced scarring or cirrhosis. The test is often used in people with chronic liver conditions such as hepatitis B, hepatitis C, alcohol-related liver disease, and fatty liver disease, now often called MASLD when linked to metabolic risk factors. FibroTest does not diagnose the cause of liver disease by itself, and it can be misleading during certain conditions such as hemolysis, Gilbert syndrome, acute inflammation, or bile duct blockage.
- FibroTest, also called FibroSure in the U.S., estimates liver fibrosis using a blood-based algorithm.
- The score runs from 0.00 to 1.00; about 0.00–0.21 usually corresponds to no fibrosis, while 0.75–1.00 usually corresponds to cirrhosis.
- The test uses alpha-2-macroglobulin, haptoglobin, apolipoprotein A1, GGT, total bilirubin, age, and sex.
- A high FibroTest score suggests a higher chance of significant scarring, but it does not prove the cause of liver disease.
- Results need careful review if you recently had acute hepatitis, infection, hemolysis, jaundice, gallstones, or known Gilbert syndrome.
- Follow-up may include liver enzymes, platelet count, FIB-4, ultrasound, elastography, viral hepatitis testing, or a liver specialist referral.
Table of Contents
- What FibroTest Measures
- How the Score Is Calculated
- FibroTest Normal Range and Fibrosis Stages
- How to Interpret Results
- When the Test Is Used
- FibroTest vs FibroSure and Other Fibrosis Tests
- Factors That Can Make Results Less Reliable
- What to Do After Results
What FibroTest Measures
FibroTest estimates the amount of fibrosis in the liver. Fibrosis is scar tissue that forms when the liver has been irritated or injured for a long time. The injury may come from viral hepatitis, alcohol, metabolic fatty liver disease, autoimmune disease, bile duct disease, iron overload, medication injury, or other chronic liver problems.
Fibrosis is important because it gives a better picture of long-term liver risk than a single liver enzyme result. A person can have serious fibrosis with only mildly abnormal ALT or AST, and another person can have high liver enzymes from a temporary injury without advanced scarring. That is why fibrosis scores are often used together with liver enzymes, imaging, and the medical history rather than as a stand-alone answer.
FibroTest does not look directly at the liver. It uses blood markers that tend to shift when fibrosis, inflammation, bile flow problems, or changes in liver protein handling are present. The result is then translated into a score that roughly corresponds to the METAVIR fibrosis scale, a staging system commonly used in liver biopsy reports.
The METAVIR fibrosis stages are:
- F0: no fibrosis
- F1: mild fibrosis
- F2: moderate or clinically significant fibrosis
- F3: advanced fibrosis or bridging fibrosis
- F4: cirrhosis
Cirrhosis means the liver has developed widespread scarring and structural change. It does not always mean liver failure. Many people with compensated cirrhosis feel well and have fairly stable blood tests. Still, cirrhosis changes follow-up because it may require screening for liver cancer, checking for portal hypertension, reviewing medicines and alcohol exposure, and monitoring for complications.
FibroTest is often ordered after abnormal liver tests, known fatty liver, chronic viral hepatitis, or a previously elevated fibrosis score. It may be used alongside a liver function tests panel, imaging, or other noninvasive fibrosis tools.
How the Score Is Calculated
FibroTest uses a patented algorithm. The exact calculation is usually performed by the reporting laboratory or the licensed test platform, not by the clinician manually. The important part for patients is understanding which markers feed the score and why abnormal values can push the result higher or lower.
The usual FibroTest components are:
- Alpha-2-macroglobulin
- Haptoglobin
- Apolipoprotein A1
- Gamma-glutamyl transferase, often shortened to GGT
- Total bilirubin
- Age
- Sex
Some related panels also include ALT to estimate inflammatory activity. That activity score may be reported as ActiTest or as part of a larger FibroSure-style panel. ALT is not the same as fibrosis. ALT rises when liver cells are irritated or injured, while fibrosis refers to scar tissue. A person can have both inflammation and fibrosis, but one does not always match the other.
Alpha-2-macroglobulin tends to rise with fibrosis and tissue remodeling. Haptoglobin can fall for reasons related to the liver, but it also falls when red blood cells break down in the bloodstream, a process called hemolysis. Apolipoprotein A1 is linked to HDL-related protein production and can be lower in more advanced liver disease or poor nutrition. GGT and bilirubin can rise with liver or bile duct stress. Age matters because fibrosis risk often increases over time in chronic liver disease.
Because the test combines several markers, no single component should be interpreted as the whole result. A mildly high GGT, for example, does not automatically mean advanced fibrosis. A low haptoglobin from hemolysis can falsely raise concern. A high bilirubin from Gilbert syndrome can distort the score even when the liver itself is not scarred.
This is why FibroTest is best read with the surrounding pattern. Doctors often compare it with ALT, AST, platelet count, albumin, INR, bilirubin fractionation, viral hepatitis tests, metabolic risk markers, and imaging. When ALT and AST are part of the broader picture, an article on ALT and AST patterns can help explain why enzyme elevation and fibrosis risk do not always move together.
FibroTest Normal Range and Fibrosis Stages
FibroTest does not have a “normal range” in the same way that sodium, hemoglobin, or albumin does. The score is a probability-style fibrosis estimate from 0.00 to 1.00. Lower is generally better. Higher suggests a greater chance of liver scarring.
Many reports translate the number into an estimated fibrosis stage. The exact wording may vary by lab, and some reports combine stages because noninvasive tests cannot always separate neighboring stages cleanly.
| FibroTest score | Approximate fibrosis stage | General meaning |
|---|---|---|
| 0.00–0.21 | F0 | No fibrosis suggested |
| 0.22–0.27 | F0–F1 | No to minimal fibrosis |
| 0.28–0.31 | F1 | Mild fibrosis |
| 0.32–0.48 | F1–F2 | Mild to moderate fibrosis |
| 0.49–0.58 | F2 | Moderate fibrosis |
| 0.59–0.72 | F3 | Advanced fibrosis |
| 0.73–0.74 | F3–F4 | Advanced fibrosis to possible cirrhosis |
| 0.75–1.00 | F4 | Cirrhosis suggested |
A “normal” FibroTest result usually means a low score, often in the F0 or F0–F1 range. That does not mean the liver is perfectly healthy. It means the test does not suggest meaningful scarring at the time of testing. Someone with fatty liver, hepatitis, alcohol exposure, or abnormal liver enzymes may still need treatment or monitoring even when the fibrosis score is low.
A borderline or middle result needs more context. Scores around the F1–F2 or F2 range may lead to repeat testing, elastography, or closer follow-up, especially if liver enzymes remain abnormal or metabolic risk factors are present.
A high result, especially F3 or F4, deserves prompt review. It does not automatically prove cirrhosis, but it raises enough concern that clinicians usually look for confirmation with additional testing. That may include transient elastography, ultrasound, platelet count trends, albumin, INR, bilirubin, spleen size, or referral to hepatology. If cirrhosis is confirmed or strongly suspected, follow-up changes even if the person feels well.
How to Interpret Results
FibroTest results are most useful when they answer a focused clinical question: is there likely little fibrosis, significant fibrosis, advanced fibrosis, or cirrhosis? The number should not be read in isolation.
A low score can be reassuring, especially when other results also look low risk. For example, a person with mild fatty liver on ultrasound, normal platelet count, normal albumin, normal bilirubin, and a low FibroTest score is less likely to have advanced scarring. That person may still need attention to weight, insulin resistance, alcohol intake, cholesterol, or medications, but the immediate concern for advanced fibrosis is lower.
A moderate score can mean several things. It may reflect real fibrosis, especially in someone with chronic liver disease. It may also reflect a temporary distortion from inflammation, bile flow problems, or one abnormal component. In this range, doctors often compare FibroTest with other fibrosis tools rather than making a major conclusion from one result.
A high score suggests advanced fibrosis or cirrhosis, but confirmation matters. In chronic liver disease, a high fibrosis estimate may change management. It may lead to liver ultrasound surveillance, endoscopy consideration for varices, vaccination review, medication changes, alcohol avoidance counseling, and more frequent follow-up. In some cases, it may also affect eligibility for certain liver-directed treatments or specialist care.
FibroTest also has more value when the trend makes sense. A single score is a snapshot. A repeat score months or years later may show whether the risk estimate is stable, improving, or worsening. Still, small changes are not always meaningful. Lab variation, acute illness, and changes in bilirubin or haptoglobin can shift the score. A large change that matches other findings carries more weight than a small isolated movement.
It is also helpful to separate fibrosis from active injury. ALT and AST can rise quickly with liver cell irritation. Fibrosis usually develops over longer periods. A person can have high ALT from a recent medication reaction or viral illness without having advanced fibrosis. Another person can have cirrhosis with normal or near-normal ALT. When bilirubin is also abnormal, the pattern of direct and indirect bilirubin can help clarify whether jaundice is more likely from liver processing, bile flow, or red blood cell breakdown; a related discussion of direct vs indirect bilirubin patterns may be useful.
When the Test Is Used
FibroTest is used when a clinician wants a noninvasive estimate of liver scarring. It may reduce the need for liver biopsy in many routine situations, although biopsy is still used when the diagnosis is unclear, when different liver diseases may overlap, or when a precise tissue diagnosis would change treatment.
Common reasons to order FibroTest include:
- Chronic hepatitis B or hepatitis C
- Fatty liver disease linked to obesity, type 2 diabetes, insulin resistance, high triglycerides, or metabolic syndrome
- Alcohol-related liver disease
- Long-term unexplained liver enzyme elevation
- Monitoring known chronic liver disease over time
- Estimating risk when imaging suggests fatty liver, enlarged liver, nodular liver contour, or spleen enlargement
- Comparing blood-based results with elastography or other fibrosis scores
In fatty liver disease, fibrosis stage is one of the strongest signals of long-term liver risk. Simple fat in the liver may stay stable for years, but fibrosis raises concern for progression. That is why clinicians increasingly use stepwise approaches: a simple first-line score such as FIB-4, then elastography or a more specific blood-based test if risk is not clearly low. A discussion of FIB-4 and APRI can help place FibroTest among other noninvasive options.
In viral hepatitis, FibroTest can help estimate fibrosis before treatment or during follow-up. Hepatitis C is now curable for most people with direct-acting antiviral therapy, but fibrosis stage still matters because people with advanced fibrosis or cirrhosis may need long-term surveillance even after the virus is cleared. In hepatitis B, fibrosis assessment can help guide treatment discussions and monitoring.
In alcohol-related liver disease, FibroTest may support risk assessment, but timing matters. Testing during acute alcoholic hepatitis, severe inflammation, jaundice, or infection may be less reliable. A clinician may repeat the test after stabilization or use imaging and other blood tests to clarify the picture.
FibroTest is not usually the first test for sudden severe symptoms. Yellow skin or eyes, vomiting blood, black stools, confusion, severe abdominal swelling, fever with jaundice, fainting, or severe right-upper-abdominal pain needs urgent medical assessment. A fibrosis score is not designed to manage those emergencies.
FibroTest vs FibroSure and Other Fibrosis Tests
FibroTest and FibroSure generally refer to the same blood-based fibrosis algorithm. FibroTest is the name commonly used internationally, while FibroSure is commonly used in the United States. Some labs offer disease-specific panels, such as HCV FibroSure or NASH FibroSure, that may include additional activity or steatosis-related scores.
The main difference is not the idea of the test, but the exact panel, reporting format, lab platform, and clinical setting. Always read the report name and included markers. A fibrosis score, an activity score, and a steatosis score answer different questions.
Other fibrosis tests may be used before, after, or instead of FibroTest:
| Test or tool | What it uses | Common role |
|---|---|---|
| FibroTest / FibroSure | Specialized blood markers plus age and sex | Blood-based estimate of fibrosis stage |
| FIB-4 | Age, AST, ALT, platelet count | Simple first-line risk score, especially in fatty liver disease |
| APRI | AST and platelet count | Simple score used more often in viral hepatitis and resource-limited settings |
| ELF test | Direct fibrosis-related blood markers | Risk stratification for advanced fibrosis in selected settings |
| Transient elastography | Ultrasound-based liver stiffness | Imaging-based estimate of stiffness and fibrosis risk |
| Liver biopsy | Microscopic tissue sample | Most direct tissue assessment, used when noninvasive results are unclear or diagnosis requires tissue |
FIB-4 is widely used because it relies on routine labs and costs little. It is helpful for sorting people into low-risk and higher-risk groups, but it can be affected by age and platelet changes from causes outside the liver. FibroTest uses a more specialized marker set and may provide a more direct fibrosis-stage estimate, but it still has false positives and false negatives.
The ELF test is another blood-based fibrosis tool, but it measures different markers linked to extracellular matrix turnover. A separate article on the Enhanced Liver Fibrosis test may help if your report includes ELF rather than FibroTest.
Transient elastography, often known by the brand name FibroScan, measures liver stiffness. It is not a blood test. Stiffness often rises with fibrosis, but it can also rise temporarily with acute inflammation, congestion, cholestasis, recent heavy alcohol use, or eating shortly before the exam. Many clinicians like pairing a blood-based score with elastography because agreement between two different methods is more convincing than either result alone.
Liver biopsy is now less common for routine fibrosis staging than it once was. It can still be important when autoimmune hepatitis, drug injury, overlapping diseases, unexplained liver test abnormalities, or uncertain fatty liver severity are being evaluated. Biopsy can show inflammation, fat, iron, bile duct injury, and scarring pattern in a way blood tests cannot.
Factors That Can Make Results Less Reliable
FibroTest is useful, but it is not immune to misleading results. Because the score depends on bilirubin, haptoglobin, GGT, apolipoprotein A1, and alpha-2-macroglobulin, anything that changes those markers for reasons unrelated to liver fibrosis can distort the estimate.
Hemolysis is one of the classic problems. Hemolysis means red blood cells are breaking down. This can lower haptoglobin and raise bilirubin, which may make the FibroTest score look worse than the true fibrosis stage. Hemolysis can happen from certain blood disorders, mechanical heart valves, transfusion reactions, severe illness, or even a damaged blood sample.
Gilbert syndrome can also interfere. Gilbert syndrome is a common inherited condition that causes intermittent mild unconjugated bilirubin elevation. It does not usually damage the liver, but bilirubin is part of the FibroTest calculation. If bilirubin is high because of Gilbert syndrome rather than liver scarring, the fibrosis estimate may be misleading.
Bile duct blockage and cholestasis can raise bilirubin and GGT. Gallstones, bile duct narrowing, pancreatic or bile duct tumors, and some liver diseases can cause this pattern. In that setting, a high FibroTest score may reflect impaired bile flow rather than fibrosis alone. If alkaline phosphatase and GGT are high together, the distinction between liver and bile duct patterns becomes important; the article on ALP and GGT patterns explains that comparison in more detail.
Acute inflammation or infection may change several proteins used in the score. So can severe undernutrition, major systemic illness, and some inflammatory conditions. Acute hepatitis is another concern. Very high ALT from sudden liver injury does not necessarily equal chronic fibrosis, and testing during the acute phase may not give the most useful staging estimate.
Recent alcohol exposure can also complicate interpretation, especially if it raises GGT, bilirubin, or inflammation markers. This does not mean the test is useless in alcohol-related liver disease. It means the timing and the full clinical picture matter.
Practical steps can reduce confusion:
- Tell your clinician about known Gilbert syndrome, hemolytic anemia, recent infection, recent hospitalization, gallstones, bile duct disease, or heavy alcohol use.
- Avoid interpreting a fibrosis score during an obvious acute illness unless your clinician specifically needs that information.
- Compare the score with platelet count, albumin, INR, bilirubin fractions, AST, ALT, ALP, GGT, and imaging.
- Repeat or confirm testing when the result does not fit the rest of the picture.
- Use the same lab or method for follow-up when possible, because report formats and cutoffs may differ.
A high FibroTest score that appears during jaundice, infection, or suspected hemolysis should be reviewed carefully before concluding that cirrhosis is present.
What to Do After Results
The next step depends on the score, the liver condition being evaluated, and whether other results support the same conclusion.
If the score is low, follow-up usually focuses on the cause of liver stress. For fatty liver disease, that may mean improving insulin resistance, weight, waist circumference, triglycerides, blood pressure, sleep apnea, and alcohol intake. For hepatitis B or C, it may mean antiviral evaluation or ongoing monitoring. For medication-related liver injury, it may mean reviewing prescriptions, supplements, and over-the-counter drugs. A low fibrosis score should not be used as permission to ignore an ongoing liver trigger.
If the score is moderate, clinicians often look for confirmation. They may calculate FIB-4, order transient elastography, repeat liver enzymes, check platelet count, or assess for viral hepatitis, iron overload, autoimmune liver disease, or metabolic risk. Moderate results are common enough that they should be interpreted calmly, but they should not be dismissed when the risk factors are real.
If the score suggests F3 or F4, follow-up should be more deliberate. Your clinician may order ultrasound, elastography, additional liver blood tests, or refer you to a gastroenterologist or hepatologist. Blood tests such as albumin and INR help assess liver synthetic function, which is different from scarring. A person with advanced fibrosis may still have normal albumin and INR, but abnormal results can suggest reduced liver reserve. For that part of the evaluation, albumin and INR are especially relevant.
If cirrhosis is suspected or confirmed, the plan may include liver ultrasound every 6 months for liver cancer surveillance, endoscopy evaluation in selected patients, vaccination against hepatitis A and B if not immune, avoiding alcohol, careful medication review, and monitoring for ascites, varices, encephalopathy, and kidney strain. Not everyone needs every test immediately, but cirrhosis changes the monitoring schedule.
Lifestyle steps can help many chronic liver conditions, especially fatty liver disease and alcohol-related liver disease. The most useful steps are usually specific and measurable: no alcohol when advanced fibrosis is suspected, gradual weight loss if overweight, regular physical activity, better diabetes control, lower triglycerides, and avoiding unnecessary supplements. Some supplements marketed for “liver detox” can injure the liver or interact with medicines.
Ask your clinician these questions after a FibroTest result:
- What fibrosis stage does my score suggest?
- Do any of my individual markers make the result less reliable?
- Does this result match my platelet count, liver enzymes, bilirubin, imaging, and medical history?
- Should I have elastography, ultrasound, or repeat testing?
- Do I need testing for hepatitis B, hepatitis C, iron overload, autoimmune liver disease, or bile duct disease?
- How often should fibrosis be reassessed?
- Should I see a liver specialist?
The most useful FibroTest result is one that leads to a clear plan: reduce the liver injury trigger, confirm uncertain findings, monitor fibrosis risk over time, and act early when advanced scarring is possible.
References
- EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update 2021 (Guideline)
- AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease 2023 (Guideline)
- Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age 2011 (Review)
- Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease 2006 (Research Article)
- Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B 2016 (Systematic Review)
Disclaimer
FibroTest results should be interpreted by a qualified healthcare professional who can review the full liver panel, medical history, medications, imaging, and possible causes of false results. Seek urgent medical care for jaundice with fever, confusion, vomiting blood, black stools, severe abdominal swelling, fainting, or severe right-upper-abdominal pain. This article is for general education and does not replace personal medical advice.
